Pharmacokinetics, Pharmacodynamics and Dermal Distribution of 5-Methoxypsoralen Based on a Physiologically Based Pharmacokinetic Model to Support Phytotherapy Using Brosimum gaudichaudii

Abstract

The treatment of vitiligo includes the combination of psoralens and ultraviolet type A exposure. Psoralens belong to a group of natural furanocoumarins that cause the skin to become sensitive temporarily to ultraviolet type A. The aim of this study was to develop a physiologically based pharmacokinetic model of 5-MOP from Brosimum gaudichaudii to support psoralen and ultraviolet type A therapy. A study of rats was used to establish and validate rat tissue distribution. The same chemical-specific parameters used in the rat model were also employed in the human model to project human pharmacokinetics. The highest exposures in the rats were in the brain and skin. Following a single dose of 1.2 mg/kg 5-MOP in humans, the model predicted a maximum concentration of 20 ng/mL and an area under the curve of 125 ng.h/mL, matching clinical results. The half-maximum melanogenesis concentrations in B16F10 cells were 29.5, 18.5, 11.5, and 6.5 ng/mL for synthetic 5-MOP, synthetic 5-MOP with ultraviolet type A, B. gaudichaudii alone, and B. gaudichaudii plus ultraviolet type A, respectively. Physiologically based pharmacokinetic model prediction in humans supported a once-every-two-day regimen for optimal melanin production. This type of framework can be applied to support strategies for dose selection and to investigate the impact of drugs on melanocyte recovery.

Key words

vitiligo - skin - psoralen - PUVA - Brosimum gaudichaudii - Moraceae

• References

• 1 Handa S, Dogra S. Epidemiology of childhood vitiligo: a study of 625 patients from north India. Pediatr Dermatol 2003; 20: 207-210
• 2 Gupta V, Sreenivas V, Mehta M, Ramam M. What do Vitiligo Impact Scale-22 scores mean? Studying the clinical interpretation of scores using an anchor-based approach. Br J Dermatol 2019; 180: 580-585
• 3 Hill-Beuf A, Porter JD. Children coping with impaired appearance: social and psychologic influences. Gen Hosp Psychiatry 1984; 6: 294-301
• 4 Kent G, al-Abadie M. Factors affecting responses on Dermatology Life Quality Index items among vitiligo sufferers. Clin Exp Dermatol 1996; 21: 330-333
• 5 Ongenae K, Van Geel N, De Schepper S, Naeyaert JM. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol 2005; 152: 1165-1172
• 6 Middelkamp-Hup MA, Bos JD, Rius-Diaz F, Gonzalez S, Westerhof W. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol 2007; 21: 942-950
• 7 Kanwar AJ, Kumaran MS. Childhood vitiligo: treatment paradigms. Indian J Dermatol 2012; 57: 466-474
• 8 Shenoi SD, Prabhu S. Indian Association of Dermatologists, Venereologists and Leprologists. Photochemotherapy (PUVA) in psoriasis and vitiligo. Indian J Dermatol Venereol Leprol 2014; 80: 497-504
• 9 Calzavara-Pinton PG, Carlino A, Manfredi E, Semeraro F, Zane C, De Panfilis G. Ocular side effects of PUVA-treated patients refusing eye sun protection. Acta Derm Venereol Suppl (Stockh) 1994; 186: 164-165
• 10 Part 7 – Drug-induced ocular Side Effects. In: Fraunfelder FT, Fraunfelder FW, Chambers WA. eds. Clinical Ocular Toxicology: Drugs, Chemicals and Herbs. Edinburgh: W.B. Saunders; 2008: 45-287
• 11 Cunha LC, Paula JR, Sá VA, Amorim MEP, Barros ICM, Brito LAB, Silveira N. Acute toxicity of Brosimum gaudichaudii Trécul. root extract in mice: determination of both approximate and median lethal doses. Rev Bras Farmacogn 2008; 18: 532-538
• 12 Pozetti GL. Brosimum gaudichaudii Trecul (Moraceae): da planta ao medicamento. Rev Ciênc Farm Básica Apl 2009; 26: 159-166
• 13 Sy SK, Wang X, Derendorf H. Introduction to Pharmacometrics and quantitative Pharmacology with an Emphasis on physiologically based Pharmacokinetics. In: Derendorf H, Schmidt S. eds. Applied Pharmacometrics. New York: Springer; 2014: 1-64
• 14 Eichler HG, Muller M. Drug distribution. The forgotten relative in clinical pharmacokinetics. Clin Pharmacokinet 1998; 34: 95-99
• 15 Pozetti GL. [Chemical study of Brosimum gaudichaudii Trecul. 1. Isolation and identification of bergapten, and psoralene from the roots of Brosimum gaudichaudii Trecul]. Rev Fac Farm Odontol Araraquara 1969; 3: 215-223
• 16 Malcov-Brog H, Alpert A, Golan T, Parikh S, Nordlinger A, Netti F, Sheinboim D, Dror I, Thomas L, Cosson C, Gonen P, Stanevsky Y, Brenner R, Perluk T, Frand J, Elgavish S, Nevo Y, Rahat D, Tabach Y, Khaled M, Shen-Orr SS, Levy C. UV-Protection timer controls linkage between stress and pigmentation skin protection systems. Mol Cell 2018; 72: 444-456.e7
• 17 Yu XA, Azietaku JT, Li J, An M, He J, Hao J, Cao J, Chang YX. The pharmacokinetics, bioavailability and excretion of bergapten after oral and intravenous administration in rats using high performance liquid chromatography with fluorescence detection. Chem Cent J 2016; 10: 62
• 18 Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol 2011; 7: 267-286
• 19 Aubin F, Makki S, Humbert P, Muret P, Agache P. Treatment of psoriasis with a new micronized 5-methoxypsoralen tablet and UVA radiation. Arch Dermatol Res 1994; 286: 30-34
• 20 de Wolff FA, Thomas TV. Clinical pharmacokinetics of methoxsalen and other psoralens. Clin Pharmacokinet 1986; 11: 62-75
• 21 Ehrsson H, Wallin I, Ros AM, Eksborg S, Berg M. Food-induced increase in bioavailability of 5-methoxypsoralen. Eur J Clin Pharmacol 1994; 46: 375-377
• 22 Martins FS, Pascoa H, de Paula JR, da Conceicao EC. Technical aspects on production of fluid extract from Brosimum gaudichaudii Trecul roots. Pharmacogn Mag 2015; 11: 226-231
• 23 Heo SJ, Ko SC, Cha SH, Kang DH, Park HS, Choi YU, Kim D, Jung WK, Jeon YJ. Effect of phlorotannins isolated from Ecklonia cava on melanogenesis and their protective effect against photo-oxidative stress induced by UV-B radiation. Toxicol In Vitro 2009; 23: 1123-1130
• 24 Waters NJ, Jones R, Williams G, Sohal B. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J Pharm Sci 2008; 97: 4586-4595
• 25 Evans CA, Jolivette LJ, Nagilla R, Ward KW. Extrapolation of preclinical pharmacokinetics and molecular feature analysis of “discovery-like” molecules to predict human pharmacokinetics. Drug Metab Dispos 2006; 34: 1255-1265
• 26 Zucchi A, Raho E, Marconi B, Nicoli S, Santini M, Allegra F, Colombo P, Bettini R, Santi P. Plasma and skin concentration of 5-methoxypsoralen in psoriatic patients after oral administration. J Invest Dermatol 2001; 117: 379-382
• 27 Schmitt W. General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro 2008; 22: 457-467
• 28 Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006; 95: 1238-1257
• 29 Sy SK, Malmberg R, Matsushima A, Asin-Prieto E, Rosenkranz B, Cotton MF, Derendorf H, Innes S. Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model. Int J Antimicrob Agents 2015; 45: 413-419
• 30 Biesdorf C, Martins FS, Sy SKB, Diniz A. Physiologically-based pharmacokinetics of ziprasidone in pregnant women. Br J Clin Pharmacol 2019; 85: 914-923